Rupak Shivakoti, PhD, MSPH

CRS:

BJMC

Role:

Investigators

Position:

Investigator

Rupak Shivakoti, PhD, MSPH, is an Assistant Professor of Epidemiology at Columbia University Mailman School of Public Health, and a member of the faculty at the Johns Hopkins Center for Clinical Global Health Education. His formal training is in immunology, infectious diseases, and epidemiology.
 
Dr. Shivakoti’s primary research interest focuses on the central role of inflammation in HIV and TB outcomes, both in adult and maternal-infant populations. In addition, he is interested in the relationship of nutrition and gut microbiome with inflammation and health outcomes. He is the PI of NIH-funded projects related to these topics and conducted in diverse international settings, with a strong focus in India. More about Dr. Shivakoti's work can be found in the tabs below.
 
After completing his undergraduate degree in biology from DePauw University, Dr. Shivakoti received a MSPH in international health and a PhD in molecular microbiology and immunology from the Johns Hopkins Bloomberg School of Public Health. His PhD thesis, under the direction of Dr. Diane Griffin, focused on the innate and adaptive immune responses to the measles virus and measles vaccine. He completed his post-doctoral fellowship at JHU CCGHE with Dr. Amita Gupta serving as his mentor.

  • Investigator, NWCS 319, parent study A5175
  • Study Chair, NWCS 448, parent study A5331
  • Member, End-Organ Disease and Inflammation Transformative Science Group (Dec 2017-Nov 2019)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More